Literature DB >> 2023736

Reliability of visual field results over repeated testing.

J Katz1, A Sommer, K Witt.   

Abstract

Fifty-one normal subjects, 337 with ocular hypertension, and 55 patients with glaucoma underwent C-30-2 testing on the Humphrey Field Analyzer on at least three occasions over a 6-year period. The time between tests was approximately 1 year. Using the manufacturer's standard for a reliable field (false-positive and false-negative rates, less than 33%; fixation losses, less than 20%), no trends in the proportion of reliable fields or the component indices were observed over time. Four percent of normal subjects, 9% of those with ocular hypertension, and 8% of patients with glaucoma were unable to meet the reliability standard every time they were tested. This repeated lack of reliability was due almost exclusively to fixation losses. However, patients with glaucoma were more likely to have repeatedly high false-negative responses than those with ocular hypertension or normal subjects, providing further evidence that false-negative responses are more indicative of glaucoma than of patient reliability.

Entities:  

Mesh:

Year:  1991        PMID: 2023736     DOI: 10.1016/s0161-6420(91)32339-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  Use of a portable head mounted perimetry system to assess bedside visual fields.

Authors:  D A Hollander; N J Volpe; M L Moster; G T Liu; L J Balcer; K D Judy; S L Galetta
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

2.  Applying theories and interventions from behavioral medicine to understand and reduce visual field variability in patients with vision loss.

Authors:  Collin Rozanski; Jennifer A Haythornthwaite; Gislin Dagnelie; Ava K Bittner
Journal:  Med Hypotheses       Date:  2014-05-09       Impact factor: 1.538

3.  Glaucoma screening.

Authors:  A K Aggarwal
Journal:  Br J Gen Pract       Date:  1995-07       Impact factor: 5.386

4.  Influence of missed catch trials on the visual field in normal subjects.

Authors:  F Fankhauser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993       Impact factor: 3.117

5.  Detection of optic disc change with the Heidelberg retina tomograph before confirmed visual field change in ocular hypertensives converting to early glaucoma.

Authors:  D S Kamal; A C Viswanathan; D F Garway-Heath; R A Hitchings; D Poinoosawmy; C Bunce
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

6.  Use of sequential Heidelberg retina tomograph images to identify changes at the optic disc in ocular hypertensive patients at risk of developing glaucoma.

Authors:  D S Kamal; D F Garway-Heath; R A Hitchings; F W Fitzke
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

7.  Retinal nerve fiber layer defects and automated perimetry evaluation in ocular hypertensives.

Authors:  E Abecia; F M Honrubia
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

8.  Effect of a patient training video on visual field test reliability.

Authors:  H Sherafat; P G D Spry; A Waldock; J M Sparrow; J P Diamond
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

9.  Central 10-degree visual field change following non-penetrating deep sclerectomy in severe and end-stage glaucoma: preliminary results.

Authors:  Igor Leleu; Benjamin Penaud; Esther Blumen-Ohana; Thibault Rodallec; Raphaël Adam; Olivier Laplace; Jad Akesbi; Jean-Philippe Nordmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-03       Impact factor: 3.117

10.  Characterization of Central Visual Field Loss in End-stage Glaucoma by Unsupervised Artificial Intelligence.

Authors:  Mengyu Wang; Jorryt Tichelaar; Louis R Pasquale; Lucy Q Shen; Michael V Boland; Sarah R Wellik; Carlos Gustavo De Moraes; Jonathan S Myers; Pradeep Ramulu; MiYoung Kwon; Osamah J Saeedi; Hui Wang; Neda Baniasadi; Dian Li; Peter J Bex; Tobias Elze
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.